{{medical}}
{{NoteTA|G1=Chemistry|G2=Medicine}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 459589155
| IUPAC_name = (±)-4-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-α, α-dimethyl benzeneacetic acid
| image = Fexofenadine2DCSD.svg
| alt = Skeletal formula of fexofenadine
| width = 260px
| chirality = [[Racemic_mixture|Racemic mixture]]
| image2 = Fexofenadine 3D ball.png
| alt2 = Ball-and-stick model of fexofenadine
<!-- Clinical data -->
| tradename = originally Allegra, others<ref name=Brands>{{cite web|title=Fexofenadine - international brand names|url=https://www.drugs.com/international/fexofenadine.html|publisher=Drugs.com|accessdate=18 January 2017|language=en}}</ref>
| Drugs.com = {{drugs.com|monograph|fexofenadine-hydrochloride}}
| MedlinePlus = a697035
| licence_US = Fexofenadine
| pregnancy_AU = B2
| pregnancy_US = C
| legal_AU = Unscheduled
| legal_CA = OTC
| legal_UK = POM
| legal_US = OTC
| routes_of_administration = [[口服|口服]]
<!-- Pharmacokinetic data -->
| bioavailability = 30-41%<ref>{{cite journal |vauthors=Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C | title = Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability | journal = Eur J Pharm Sci | volume = 40 | issue = 2 | pages = 125–31 |date=May 2010 | pmid = 20307657 | doi = 10.1016/j.ejps.2010.03.009}}</ref>
| protein_bound = 60-70%<ref name = phk09>{{cite journal|last=Smith|first=SM|author2=Gums, JG |title=Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders.|journal=Expert Opinion on Drug Metabolism & Toxicology|date=July 2009|volume=5|issue=7|pages=813–22|doi=10.1517/17425250903044967|pmid=19545214}}</ref>
| metabolism = [[Liver|Hepatic]] (≤5% of dose)<ref name = phk09/>
| elimination_half-life = 14.4小時
| excretion = Feces (~80%) and urine (~10%) as unchanged drug<ref name = phk09/>
<!-- Identifiers -->
| IUPHAR_ligand = 4819
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 83799-24-0
| ATC_prefix = R06
| ATC_suffix = AX26
| PubChem = 3348
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00950
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3231
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = E6582LOH6V
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07958
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 5050
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 914
<!-- Chemical data -->
| C=32 | H=39 | N=1 | O=4
| molecular_weight = 501.68 g/mol
| smiles = O=C(O)C(c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4)(C)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25) 29(34)14-9-21-33-22-19-28(20-23-33)32(37, 26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8, 10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RWTNPBWLLIMQHL-UHFFFAOYSA-N
}}

'''非索非那定'''（fexofenadine），販賣藥名為'''艾來錠'''（Allegra），劑型為60mg或180mg錠劑。是[[特芬那定|特芬那定]]（Terfenadine）衍生而來的[[活性代謝物|活性代謝物]]，它是一種具有選擇性末稍H1接受體拮抗活性的[[抗組織胺藥|抗組織胺藥]]。非索非那定的兩種[[鏡像異構物|鏡像異構物]]均可顯現效力相當的抗組織胺作用，被稱為第二代抗組織胺的它不會通過[[大腦血管障壁|大腦血管障壁]]（blood brain barrier，BBB），不會有前代製品例如[[嗜睡|嗜睡]]等等的[[副作用|副作用]]。

== 適應症 ==
緩解季節性[[過敏性鼻炎|過敏性鼻炎]]引起的相關症狀，緩解慢性原發性[[蕁麻疹|蕁麻疹]]相關症狀。

== 注意事項 ==
[[果汁|果汁]]類飲料會影響藥物的吸收及降低藥效，[[葡萄柚|葡萄柚]]可以顯著降低非索非那定的血藥濃度，應該盡量避免一起服用。含有[[鋁|鋁]]或[[鎂|鎂]]的制酸劑同樣會降低藥物的吸收。另外[[酮康唑|酮康唑]]（抗黴菌藥物）或者[[红霉素|红霉素]]（抗生素）會增強此藥的吸收，使此藥的劑量增強，如果與上述藥物合用時，至少應該與此藥相隔約兩小時。

==註釋==
{{reflist}}

== 參考文獻 ==
{{refbegin}}
*[https://web.archive.org/web/20131019152959/http://www1.ndmctsgh.edu.tw/pharm/pic/medinsert/005ALL09.pdf 艾來錠劑 60 / 180公絲 仿單]
*[https://web.archive.org/web/20131019070838/http://www.tzuchi.com.tw/file/tcmj/91-5/4.htm Fexofenadine HCl (Allegra) 對於治療過敏性鼻炎效益與安全性評量的臨床試驗]
*[http://www.tcdruginfo.com/My%20Webs/Fexofenadine.html FEXOFENADINE 非索非那定]
{{refend}}

==參見==
*{{le|WebMD|WebMD}}

==外部連結==
* [http://www.patient.co.uk/showdoc/30003786/ Fexofenadine] (UK patient information leaflet)
* {{Medicinenet|fexofenadine}}

{{Antihistamines}}
{{Histaminergics}}

[[Category:H1受體拮抗劑|Y]]
[[Category:二苯甲基化合物|Category:二苯甲基化合物]]